BioMarin Pharmaceutical Inc. $BMRN Position Raised by Securian Asset Management Inc.

Securian Asset Management Inc. increased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 1.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,604 shares of the biotechnology company’s stock after purchasing an additional 197 shares during the period. Securian Asset Management Inc.’s holdings in BioMarin Pharmaceutical were worth $803,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Dodge & Cox raised its holdings in BioMarin Pharmaceutical by 1.4% during the first quarter. Dodge & Cox now owns 14,955,240 shares of the biotechnology company’s stock worth $1,057,186,000 after purchasing an additional 209,005 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of BioMarin Pharmaceutical by 127.9% in the first quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company’s stock valued at $203,987,000 after buying an additional 1,642,206 shares in the last quarter. Nuveen LLC bought a new position in shares of BioMarin Pharmaceutical in the first quarter valued at $184,475,000. Goldman Sachs Group Inc. increased its holdings in shares of BioMarin Pharmaceutical by 212.7% in the first quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock valued at $112,607,000 after buying an additional 1,083,512 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of BioMarin Pharmaceutical by 7.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,532,314 shares of the biotechnology company’s stock valued at $108,319,000 after buying an additional 108,806 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ:BMRN opened at $54.48 on Friday. The company’s fifty day moving average is $55.29 and its two-hundred day moving average is $57.28. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical Inc. has a 12-month low of $51.56 and a 12-month high of $73.51. The company has a market cap of $10.46 billion, a P/E ratio of 16.17, a price-to-earnings-growth ratio of 0.68 and a beta of 0.33.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on BMRN shares. Wolfe Research set a $95.00 price target on BioMarin Pharmaceutical and gave the company an “outperform” rating in a report on Tuesday, July 15th. Wedbush reaffirmed an “outperform” rating and issued a $94.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, August 5th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of BioMarin Pharmaceutical in a report on Friday. Zacks Research cut BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Finally, Morgan Stanley dropped their price target on BioMarin Pharmaceutical from $97.00 to $96.00 and set an “overweight” rating on the stock in a report on Tuesday, July 22nd. Thirteen equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $93.26.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.